July 12, 2011 โ€“ The Interlock-35 Fibered IDC Occlusion System has been launched in the United States and Europe. Earlier this year, the system, manufactured by Boston Scientific, received clearance from the U.S. Food and Drug Administration (FDA) and CE mark approval for obstructing or reducing blood flow in the peripheral vasculature during embolization procedures.

July 7, 2011 โ€“ The National Aeronautics and Space Administration (NASA)โ€™s Ames Research Center and The Midura Laboratory selected ImageIQ to assist in their study of space flight-induced vascular alterations in the lower leg. ImageIQ will provide customized image acquisition and analysis for a vascular research study aboard NASA's final mission of the shuttle Atlantis. scheduled for July 8. The company provides imaging analytics software engineering and visualization services for research, medical device and pharmaceutical organizations.

July 5, 2011 โ€” Janssen Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has approved Xarelto (rivaroxaban tablets), a novel, once-daily, oral anticoagulant for the prevention (prophylaxis) of deep vein thrombosis (DVT) which may lead to a pulmonary embolism (PE) in people undergoing knee or hip replacement surgery.

July 5, 2011 โ€” ECRI Institute, an independent nonprofit that researches the best approaches to improving patient care, and the Health Care Improvement Foundation, an independent nonprofit corporation with a multi-dimensional focus on healthcare safety, announced the launch of a new Partnership for Patient Care regional collaborative focused on improving computed tomography (CT) radiation safety. Jointly funded by Philadelphia-area hospitals and Independence Blue Cross, this collaborative will engage hospitals and imaging centers in Philadelphia and surrounding counties in a 12-month project aimed at strengthening patient safety specific to CT imaging.

July 5, 2011 โ€“ A statement was issued by Peter W. Carmel, M.D., the president of the American Medical Association (AMA), regarding cuts to Medicare payments for diagnostic imaging.

June 30, 2011 โ€” Micell Technologies Inc. announced that it has completed its review of the scheduled four-month follow-up on the first 10 patients from the DESSOLVE I first-in-human trial of the MiStent drug-eluting coronary stent system ("MiStent DES"), an ultra-thin drug-eluting stent (DES) distinguished by a rapid-absorbing drug/polymer coating formulation. Based on results observed in the DESSOLVE I trial, Micell has reduced the sample size in its DESSOLVE II CE Mark study from 270 to 171 planned subjects.

June 30, 2011 โ€” The MemorialCare Heart and Vascular Institute (MHVI) at Long Beach Memorial has acquired the C7-XR OCT intravascular imaging system from St. Jude Medical. It is an imaging technology platform that aids physicians in the diagnosis and treatment of cardiovascular disease. Using optical coherence tomography (OCT), the system utilizes near-infrared light to create images that go beyond older coronary imaging technologies - such as fluoroscopy and intravascular ultrasound (IVUS) - offering cardiologists an assessment method with enhanced clarity for their patients with coronary artery disease.

June 30, 2011 โ€” Genzyme, a Sanofi company, and Isis Pharmaceuticals Inc. announced today that two additional analyses from phase 3 studies of mipomersen were presented at the 79th European Atherosclerosis Society (EAS) congress.

Subscribe Now